North Star Investment Management Corp. Increases Stake in Simulations Plus, Inc. $SLP

North Star Investment Management Corp. lifted its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 17.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 197,330 shares of the technology company’s stock after buying an additional 29,200 shares during the quarter. North Star Investment Management Corp.’s holdings in Simulations Plus were worth $2,332,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Simulations Plus in the 2nd quarter valued at $25,000. Quarry LP acquired a new position in shares of Simulations Plus during the third quarter worth $28,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Simulations Plus by 343.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock worth $73,000 after purchasing an additional 3,084 shares in the last quarter. US Bancorp DE increased its holdings in Simulations Plus by 32.5% in the third quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock valued at $93,000 after buying an additional 1,513 shares during the last quarter. Finally, CWM LLC increased its holdings in Simulations Plus by 160.2% in the fourth quarter. CWM LLC now owns 5,480 shares of the technology company’s stock valued at $100,000 after buying an additional 3,374 shares during the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Stock Performance

Shares of Simulations Plus stock opened at $18.20 on Monday. The company has a fifty day simple moving average of $15.81 and a 200-day simple moving average of $15.53. The stock has a market cap of $367.64 million, a price-to-earnings ratio of -5.81 and a beta of 1.32. Simulations Plus, Inc. has a 12-month low of $11.09 and a 12-month high of $21.01.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.27 by $0.08. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. The firm had revenue of $24.29 million for the quarter, compared to analyst estimates of $21.66 million. On average, analysts forecast that Simulations Plus, Inc. will post 0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wall Street Zen downgraded Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. William Blair cut Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Craig Hallum downgraded Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective on the stock. in a report on Thursday, June 18th. Weiss Ratings raised Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Finally, TD Cowen decreased their target price on Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, April 10th. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $20.90.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.